Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in …
Biotechnology
US, San Carlos [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -53.24 | -63.07 | -41.16 | |
| Graham Fair Price | 9.62 | 18.44 | 16.82 | |
| PEG | -23.87 | 0.35 | -0.47 | |
| Price/Book | 1.67 | 3.76 | 3.70 | |
| Price/Cash Flow | 45.50 | -43.54 | -79.88 | |
| Prices/Earnings | -40.23 | -19.61 | -13.98 | |
| Price/Sales | 0.00 | 0.00 | 0.00 | |
| Price/FCF | 45.50 | -43.54 | -79.88 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.00 | 0.00 | 0.00 | |
| Operating Margin | 0.00 | 0.00 | 0.00 | |
| ROA | 26.64 | -0.05 | -0.06 | |
| ROE | -0.07 | -0.05 | 27.50 | |
| ROIC | -0.08 | -0.05 | 41.05 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.06 | -0.09 | 32.90 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.30 | 0.06 | -80.06 | |
| EPS QOQ | -0.30 | 0.55 | 84.21 | |
| FCF QOQ | -0.07 | 0.08 | 11.72 | |
| Revenue QOQ | 0.00 | -1.00 | -100.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 362.59 | 100.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 0.00 | 0.00 | |
| Inventory Turnover | 0.00 | 0.25 | 100.00 | |
| Debt/Capitalization | < 0.005 | 0.01 | 39.84 | |
| Quick Ratio | 14.86 | 17.25 | 16.12 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 13.80 | 17.76 | 28.75 | |
| Cash | 12.45 | 13.31 | 6.91 | |
| Capex | -0.07 | -0.11 | -49.73 | |
| Free Cash Flow | -0.64 | -1.53 | -140.16 | |
| Revenue | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad